Literature DB >> 19474411

Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.

H Shimada1, S Hirano, H Shinotoh, A Aotsuka, K Sato, N Tanaka, T Ota, M Asahina, K Fukushi, S Kuwabara, T Hattori, T Suhara, T Irie.   

Abstract

OBJECTIVE: To characterize brain cholinergic deficits in Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB).
METHODS: Participants included 18 patients with PD, 21 patients with PDD/DLB, and 26 healthy controls. The PD group consisted of nine patients with early PD, each with a disease duration of less than 3 years, five of whom were de novo PD patients, and nine patients with advanced PD, each with a disease duration greater than or equal to 3 years. The PDD/DLB group consisted of 10 patients with PDD and 11 patients with DLB. All subjects underwent PET scans with N-[11C]-methyl-4-piperidyl acetate to measure brain acetylcholinesterase (AChE) activity. Brain AChE activity levels were estimated voxel-by-voxel in a three-compartment analysis using the arterial input function, and compared among our subject groups through both voxel-based analysis using the statistical parametric mapping software SPM5 and volume-of-interest analysis.
RESULTS: Among patients with PD, AChE activity was significantly decreased in the cerebral cortex and especially in the medial occipital cortex (% reduction compared with the normal mean = -12%) (false discovery rate-corrected p value <0.01). Patients with PDD/DLB, however, had even lower AChE activity in the cerebral cortex (% reduction = -27%) (p < 0.01). There was no significant difference between early PD and advanced PD groups or between DLB and PDD groups in the amount by which regional AChE activity in the brain was reduced.
CONCLUSIONS: Brain cholinergic dysfunction occurs in the cerebral cortex, especially in the medial occipital cortex. It begins in early Parkinson disease, and is more widespread and profound in both Parkinson disease with dementia and dementia with Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474411     DOI: 10.1212/WNL.0b013e3181ab2b58

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  105 in total

1.  Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction?

Authors:  Tamara G Fong; Sharon K Inouye; Weiying Dai; Daniel Z Press; David C Alsop
Journal:  Brain Imaging Behav       Date:  2011-03       Impact factor: 3.978

2.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 3.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

4.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

Review 5.  Mild cognitive impairment exists in Parkinson's disease.

Authors:  Irena Rektorova
Journal:  J Neural Transm (Vienna)       Date:  2011-06-19       Impact factor: 3.575

Review 6.  PET/CT in diagnosis of dementia.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

Review 7.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

Review 8.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

9.  Cholinergic Oculomotor Nucleus Activity Is Induced by REM Sleep Deprivation Negatively Impacting on Cognition.

Authors:  Patrícia Dos Santos; Adriano D S Targa; Ana Carolina D Noseda; Lais S Rodrigues; Juliane Fagotti; Marcelo M S Lima
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

10.  Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Vikas Kotagal; Robert A Koeppe; Michael A Kilbourn; Roger L Albin; Kirk A Frey
Journal:  Brain       Date:  2010-04-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.